Want to see EOLS full AI Analyst Report?
EOLS Stock Chart & Stats
$4.69
-$0.47(-4.38%)
At close: 4:00 PM EST
$4.69
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$3.86 - $10.20
Previous CloseN/A
Volume344.54K
Average Volume (3M)775.09K
Market Cap
$377.35M
Enterprise Value$383.03
Total Cash (Recent Filing)$49.79M
Total Debt (Recent Filing)$164.90M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding65,854,750
10 Day Avg. Volume873,762
30 Day Avg. Volume775,090
Financial Highlights & Ratios
PEG Ratio6.73
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.50Price Target Upside209.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$330.45M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & Healthy Gross MarginsSustained top-line expansion paired with ~65% gross margins indicates durable product economics and pricing power for Jeuveau. High gross margins provide a structural cushion to absorb SG&A investments and support eventual operating leverage as volumes scale and fixed costs are spread over higher sales.
Profitability Momentum And Credible GuidanceConsecutive quarters of positive adjusted EBITDA and management’s reiterated full‑year guidance signal improving operating discipline. This suggests sustainable operating-margin improvement potential over 2–6 months as commercial efficiencies, pricing stability and cost controls convert healthy gross margins into consistent positive cash generation.
Portfolio Expansion Via Capital-efficient Profhilo Deal And PipelineThe Profhilo license adds a non‑toxin injectable without upfront capital, widening addressable market and practitioner options while preserving cash. Coupled with planned Esteem/Sculp launches, this diversifies revenue streams and reduces reliance on a single product, strengthening medium-term resilience and cross-sell potential.
Bears Say
High Leverage And Negative EquityNegative equity and elevated debt materially constrain financial flexibility and increase refinancing risk. A levered balance sheet limits the firm's ability to invest opportunistically, raises borrowing costs under stress, and makes the company more vulnerable if cash generation slows or capital markets tighten.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means Evolus still depends on external capital to fund operations. Even with improving EBITDA, ongoing cash deficits impair self-funding capability, increase dilution or borrowing risk, and undermine long-term sustainability until internal cash generation consistently turns positive.
Structural Competition And Tariff ExposureCompetitive entrants in neurotoxins and an emerging tariff on key markets create sustained pressure on pricing, share and margins. These structural challenges require ongoing investment in sales, marketing and possibly pricing concessions, which can erode incremental margins and slow durable market-share gains.
Evolus News
EOLS FAQ
What was Evolus, Inc.’s price range in the past 12 months?
Evolus, Inc. lowest stock price was $3.86 and its highest was $10.20 in the past 12 months.
What is Evolus, Inc.’s market cap?
Evolus, Inc.’s market cap is $377.35M.
When is Evolus, Inc.’s upcoming earnings report date?
Evolus, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 14 days.
How were Evolus, Inc.’s earnings last quarter?
Evolus, Inc. released its earnings results on May 04, 2026. The company reported -$0.046 earnings per share for the quarter, beating the consensus estimate of -$0.113 by $0.067.
Is Evolus, Inc. overvalued?
According to Wall Street analysts Evolus, Inc.’s price is currently Undervalued.
Does Evolus, Inc. pay dividends?
Evolus, Inc. does not currently pay dividends.
What is Evolus, Inc.’s EPS estimate?
Evolus, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Evolus, Inc. have?
Evolus, Inc. has 65,854,750 shares outstanding.
What happened to Evolus, Inc.’s price movement after its last earnings report?
Evolus, Inc. reported an EPS of -$0.046 in its last earnings report, beating expectations of -$0.113. Following the earnings report the stock price went up 14.158%.
Which hedge fund is a major shareholder of Evolus, Inc.?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (209.17% Upside)
$14.50 (209.17% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-37.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.41%
Trailing 12-Months
Company Description
Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
EOLS Stock 12 Month Forecast
Average Price Target
$14.50
▲(209.17% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.13% Insiders
7.96% Mutual Funds
1.55% Other Institutional Investors
75.34% Public Companies and
Individual Investors